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Abstract
The HIV-1 characteristics associated with mother to child transmission (MTCT) are still poorly understood and if known
would indicate where intervention strategies should be targeted. In contrast to horizontally infected individuals, exposed
infants possess inherited antibodies (Abs) from their mother with the potential to protect against infection. We investigated
the HIV-1 gp160 envelope proteins from seven transmitting mothers (TM) whose children were infected either during
gestation or soon after delivery and from four non-transmitting mothers (NTM) with similar viral loads and CD4 counts.
Using pseudo-typed viruses we tested gp160 envelope glycoproteins for TZM-bl infectivity, CD4 and CCR5 interactions, DCSIGN capture and transfer and neutralization with an array of common neutralizing Abs (NAbs) (2F5, 2G12, 4E10 and b12) as
well as mother and infant plasma. We found no viral correlates associated with HIV-1 MTCT nor did we find differences in
neutralization with the panel of NAbs. We did, however, find that TM possessed significantly higher plasma neutralization
capacities than NTM (P = 0.002). Furthermore, we found that in utero (IU) TM had a higher neutralization capacity than
mothers transmitting either peri-partum (PP) or via breastfeeding (BF) (P = 0.002). Plasma from children infected IU
neutralized viruses carrying autologous gp160 viral envelopes as well as those from their corresponding mothers whilst
plasma from children infected PP and/or BF demonstrated poor neutralizing capacity. Our results demonstrate heightened
autologous NAb responses against gp120/gp41 can associate with a greater risk of HIV-1 MTCT and more specifically in
those infants infected IU. Although the number of HIV-1 transmitting pairs is low our results indicate that autologous NAb
responses in mothers and infants do not protect against MTCT and may in fact be detrimental when considering IU HIV-1
transmissions.
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number of infections in Russia [3]. Little is known regarding
mechanisms determining risk of MTCT but better understanding
of such events will be critical in designing effective means to limit
transmissions.
As seen with HIV-1 sexual transmission the established viruses
in MTCT predominantly utilize the CCR5 coreceptor (R5) for cell
entry and rarely CXCR4 (X4) [4,5]. Earlier studies have indicated
that HIV-1 transmissions are initiated by a single or limited
number of donor viruses, often a minor variant, indicating a
bottleneck in transmission or selective outgrowth of transmitted
variants [6,7]. Much attention has focused on defining the genetic
and phenotypic properties of the HIV-1 gp120/gp41 envelope
glycoprotein (Env) of HIV-1 since this directs the receptor and
coreceptor interactions that determine infection. The Env is also
the major target of the host immune response and induces binding
antibodies (Abs), some of which are neutralizing (NAbs) that can

Introduction
According to the 2011 UNAIDS Progress report an estimated
2.7 million people worldwide were newly infected with HIV-1 in
2010. Of this 390,000 were infants with the majority resulting
from mother-to-child transmission (MTCT). Known maternal risk
factors associated with MTCT are high plasma viral loads, low
CD4 T-cell numbers coinciding with advanced maternal immune
deficiency and prolonged labor [1]. In populations where
replacement feeding is not feasible it has been estimated that
41% of MTCT occur in utero (IU), 20% peri-partum (PP) and the
remaining 39% during prolonged breastfeeding (BF) [2]. The
majority of transmissions are found in regions where antiretroviral
therapy availability is limited, such as sub-Saharan Africa
(UNAIDS Progress report 2011) and specifically regions where
HIV-1 subtype A and C predominate, including the growing
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vaginal secretions during IP and/or virus present in breast milk
during feeding. Experiments using ex vivo fetal oral and intestinal
tissue model systems have indicated that infectious cell free HIV-1
can traverse the oral as well as intestinal mucosa and that HIV-1
infected macrophages can also transmigrate across these surfaces
[40]. To a lesser extent HIV-1 infected lymphocytes were able to
cross the intestinal epithelium and establish infection. It has been
widely postulated that HIV-1 mucosal infection can be heightened
through the interaction of virus with an array of C-type lectins,
including DC-SIGN, expressed on dendritic cells (DCs) lying
below the mucosal epithelium [41–43]. One study associating a
specific DC-SIGN genetic polymorphism with risk of HIV-1
infection indeed suggests that this molecule has a role to play in
viral transmission [44]. DC-SIGN allows for the capture of virus
and its heightened transfer to CD4+ lymphocytes, termed transinfection. We have shown that this mechanism can be enhanced
when virus is coated with Abs and taken up via the Fc receptor on
DCs and that the neutralization effects of numerous Abs can be
negated through such an interaction [45]. A number of
glycoproteins present in human bodily secretions, including milk,
have been reported to bind DC-SIGN and block HIV-1 capture
[46–49]. One such molecule, bile-salt stimulated lipase (BSSL)
from milk, is highly polymorphic with the variant forms
differentially inhibiting viral capture and infection of CD4+
lymphocytes [49]. How well virus interacts with DC-SIGN or
escapes natural inhibitors may provide the virus with a phenotypic
advantage in MTCT.
Here we study Env pseudo-typed viruses generated from TM,
NTM and their children to identify phenotypes that associate with
the risk of MTCT. From this analysis we conclude that strong
autologous neutralization activity can associate with risk of
transmission indicating that high gp120/gp41 NAb responses
may in fact be detrimental.

control or prevent infection [8–10]. There has been much
speculation that viral fitness may determine MTCT with some
studies showing that viruses from transmitting mothers (TM)
possess higher replication capacities than viruses generated from
non-transmitting mothers (NTM) [11,12]. Two studies found no
difference in infectivity between mothers and children’s env clones
tested in a single-cycle assay [13,14]. A study comparing Env
pseudo-typed viruses generated from subtype C infected MTCT
pairs demonstrated that Env from children have a higher
replication capacity than Env from the mothers which is V1V5
restricted [15]. Additionally, no differences were found between
transmitted and non-transmitted viruses for their capacity to utilize
CD4 or the CCR5 corceptor [13,14,16].
Studies of adult HIV-1 transmission pairs in Africa have shown
that viruses undergoing horizontal transmission possess Env
genotypes with shorter variable loops and fewer numbers of
potential N-linked glycosylation sites (PNGS) which can associate
with the development of anti-HIV-1 Ab responses [17]. Correlations between variable loop length and number of putative PNGS
have been reported for MTCT. In some studies fewer Env PNGS
are found in the transmitted viral variants whilst other studies do
not find differences in total number but have found the position of
the PNGS to associate with risk of transmission [14,18–20].
In MTCT Abs are present in the exposed child having been
passed from the mother. The common perception is that these Abs
protect against HIV-1 infection or select variants undergoing
transmission. In agreement with this notion, animal models
indicate that Abs can reduce or prevent MTCT [21–23]. Reports
on human mother child pairs have shown better neutralization by
NTM than by TM suggesting a protective role by Abs [24,25].
Others report better neutralization by TM or find no differences
between TM and NTM [12,14,18,24,26–29]. Neutralization
resistance in children against mother’s plasma or serum has been
reported suggesting transmission of neutralization escape mutants,
but, in contrast, sensitivity for neutralization by plasma of the
mother has also been found [18,24,26,27,30,31]. These discrepancies may depend on differences in viral subtype, mode of
transmission, timing of transmission, timing of sampling or the
selective study of autologous versus non-autologous viruses.
Although the role of maternal NAbs in MTCT is controversial
trials with HIV-Ig have been conducted. One demonstrated
protection against IU transmission whilst the other revealed a
significant increase in the number of infections at birth and 2
weeks after delivery in the treated versus untreated group [32,33].
IgG transport from the placenta to the fetus during gestation is
mediated by the FcRn receptors expressed on the syncytiotrophoblast followed by transcytosis [34]. The FcRn receptor is also
expressed on intestinal mucosa and functions in the uptake of IgG
from breast milk. Although the FcRn receptor binds monomeric
IgG more avidly than aggregated or immunocomplexed IgG the
mechanism may provide a route whereby HIV-1/anti-HIV-1 IgG
complexes can be transferred to the fetus [35]. Total IgG binding
to gp160, gp120 glycoproteins and/or peptides derived from V3
or gp41 was measured in TM and NTM individuals with better
binding found in the TM, which may be in line with heightened
enhancement to transcytosis of HIV-1 via HIV/IgG complexes
[12,36–38]. In addition, it has been demonstrated in studies
utilizing a trophoblast monolayer model mimicking the barrier
between the placenta and fetal blood that the fusion of HIV-1
infected PBMCs, monocytes and macrophages at the apical side of
the monolayer can be followed by HIV-1 transcytosis to the lateral
side [35,39].
HIV-1 MTCT requires passage of virus across a mucosal
barrier, be it via the amniotic fluid during IU, from blood and
PLOS ONE | www.plosone.org

Results
Selection of env Clones for Study
From a cohort of 30 pregnant HIV-1 positive women from
Rwanda we generated Env pseudo-typed viruses from seven
MTCT pairs (090/091, 100/101, 130/131, 250/251, 290/291,
300/301 and 370/371), four infected IU and three PP or BF
(Table 1). We included a group of four NTM (160, 200, 270 and
380) infected with similar viral loads and CD4 counts. We
generated pseudo-typed viruses expressing whole gp160 Env
derived from plasma of mothers and children and screened for
infectivity on TZM-bl cells. The env clones that gave rise to
infectious pseudo-typed viruses were sequenced and subjected to
phylogenetic analysis (Fig. 1). This analysis confirmed the
relatedness of the virus circulating in the respective mother child
pairs. One transmission pair (130/131) was infected with subtype
C virus, five pairs were infected with subtype A (090/091, 100/
101, 290/291, 300/301 and 370/371) and one pair (250/251)
carried an AC recombinant. Three NTM (160, 200, and 380)
harbored a subtype A virus and one (270) subtype C. Earlier
analysis on this cohort showed that six out of the seven pairs
demonstrated transmission of a single virus variant, whilst pair 90/
91 showed transmission of two variants [20] (Fig. 1). Since the viral
population in each child was homogenous we selected one clone
from each for analysis, with exception of child 091 where both
variants were analyzed. For each TM and NTM we randomly
selected two variants. From three TM and two NTM the clones
were shown to closely cluster and from mothers 300, 290, 370 and
090 only two variants were available and both were utilized. From
mother 100 we selected a third variant (100P37) based on
2
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Figure 1. Phylogenetic analysis of the gp160 envelope region. The analysis was performed using the Neighbor-Joining (N-J) method of MEGA
version 4. Positions containing an alignment gap were included for pair-wise sequence analysis. TM depicted by closed circles, IC by open circles and
NTM by triangles. The clones selected for further analyses are indicated with an asterix.
doi:10.1371/journal.pone.0069274.g001

separately no significant differences in IC50 values were found
between NTM, TM and children. We can conclude that enhanced
affinity for the CCR5 coreceptor was not providing selection in
MTCT.

sequence prediction indicating it to be a R5/X4 dual-tropic virus.
We investigated the constructed Env pseudo-typed viruses from
NTM, TM and IC for properties such as entry, receptor and
coreceptor usage, interaction with DC-SIGN as well as neutralization sensitivity.

No Differences in Env Interaction with DC-SIGN or
Efficiency of virus Transfer from DC-SIGN Bound viruses
to TZM-bl Cells from TM, NTM or Children

Env Pseudo-typed viruses from TM and NTM more
Infectious than viruses from Children
We tested the infectivity of all pseudo-typed viruses from NTM,
TM and children in the TZM-bl single-cycle infection assay.
Limiting dilutions of the viral stock was performed to determine
that the readings were within the linear range when testing up to
5 ng CA-p24 input. The infectivity median was determined by
measuring the Relative Luciferase Units (RLU) normalized to the
amount of capsid p24 (CA-p24) (Fig. 2). We found no difference
between viruses of NTM and TM but the children’s virus clones
showed significantly lower entry efficiency than the TM (P = 0.04)
indicating that high infectivity is not associated with virus selection
during transmission.

Since it has previously been shown that DC-SIGN polymorphisms can associate with risk of transmission [44] and that factors
found in bodily secretions, such as breast milk, can bind this
molecule [49] we choose to study how our HIV-1 pseudo-typed
viruses interacted with this specific C-type lectin. To determine
whether there is a role of DC-SIGN selection in MTCT in our
cohort we examined the interaction of the selected pseudo-typed
viruses in a DC-SIGN capture assay (Fig. 4A). We found no
significant differences between Env pseudo-typed viruses between
NTM, TM and children. We subsequently tested the transfer of
DC-SIGN captured pseudo-typed viruses to TZM-bl cells to
mimic in vivo transfer to CD4+ lymphocytes (Fig. 4B). We found no
differences in infection of transferred pseudo-typed viruses
between NTM and TM, but the transfer by children viruses
tended to be lower (P = 0.07) reflecting the lower direct infectivity
previously observed with the same viruses (Fig. 2). Since DC-SIGN
binding is influenced by the gp120 glycan composition we
investigated the correlation between the number of PNGS in the
V1V5 region of the pseudo-typed viruses and the levels of CA-p24
captured by DC-SIGN (Fig. 4C and 4D). We found a significant
correlation between viruses from TM and NTM (r2 = 0.2,
P = 0.03) (Fig. 4C) but no correlation in the clade C viruses
suggesting another selection for these glycans opposed to DCSIGN binding (Fig. 4D). In conclusion we found no evidence of
enhanced capture or efficiency of transfer to TZM-bl cells for the
viruses undergoing MTCT in our cohort.

No Differences in virus Affinity for CD4 between TM, NTM
or Children
We examined the affinity for the CD4 receptor by incubating
the selected pseudo-typed viruses with increasing concentrations of
sCD4 on TZM-bl cells (Fig. 3A). The median 50% inhibitory
concentration (IC50) of sCD4 in the pseudo-typed viruses from
TM tended to be lower than the median in the NTM (P = 0.06)
suggesting higher affinity for the CD4 receptor in the TM group.
The median IC50 of sCD4 in TM and children was not
significantly different. We also measured the effect of CD4
directed monoclonal Ab OKT4 by incubating TZM-bl cells with
increasing concentrations of OKT4 before infection with pseudotyped viruses (Fig. 3B). No difference was found in the median
IC50 of OKT4 in the NTM compared with the IC50 in TM, but
the median IC50 in the children tended to be lower than in TM
(P = 0.06), suggesting lower affinity for the CD4 receptor of viruses
from children compared to mothers. In conclusion, no evidence
was found for transmission selection of viruses with higher affinity
for the CD4 receptor in our cohort.

No Difference in Sensitivity of Env Pseudo-typed viruses
from TM, NTM or Children to Potent NAbs
Using the TZM-bl neutralization assay we tested the sensitivity
profile of our selected pseudo-typed viruses to a panel of well
characterized human NAbs; IgG1b12 (b12) directed to the CD4
binding site, glycan dependent 2G12 and the gp41 Membrane
Proximal External Repeat (MPER) NAbs 2F5 and 4E10 (Table 2).
We found that all pseudo-typed env clones were sensitive to
neutralization by 4E10. The IgG1b12 epitope was present in the
viruses of five transmission pairs (90/91, 130/131, 250/251, 300/
301 and 370/371), the viruses of two of them (300/301, 370/371)
were resistant to neutralization by b12. Two of the 3 clones of
mother 100 and the clone of child 301 were resistant to 2G12 in
spite of possession of al the 5 Putative N-Glycosylaton Sites
(PNGS) associated with neutralization. The clones of TM 90 and
300 were resistant to 2G12 whilst one of the two clones of child 91
and the clone of child 301 showed sensitivity to neutralization. The
subtype C variants of transmission pair 130/131 and NTM 270,
with an ARQ mutation at the C terminal of the 2F5 epitope,
provided resistance to this NAb. A negative correlation was found
between the length of variable loop V4 and the IC50 values with
4E10 (r2 = 0.152, P = 0.032) and the IC50 values of 2F5 (r2 = 0.13,
P = 0.0009) (data not shown). Overall we found no significant

No Differences in NTM, TM or Children’s virus Interacting
with the CCR5 Coreceptor
We next determined whether there were differences in virus
coreceptor utilization between the different groups. Initially we
determined the coreceptor usage of the Env pseudo-typed viruses
by incubating TZM-bl cells with the CXCR4 inhibitor ADM3100,
with the CCR5 inhibitor Maraviroc and with both before infection
with the selected pseudo-typed viruses. One variant from TM 100
was found to be dual-tropic for CCR5 and CXCR4 whilst all
other Env’s from NTM, TM and children were exclusively CCR5
using. We then examined the affinity of the Env pseudo-typed
viruses for the CCR5 receptor by incubating TZM-bl cells with
increasing concentrations of Maraviroc and determining IC50
values (Fig. 3C). The dual-tropic clone of mother 100 was
excluded from this analysis. We found no significant differences
between the three groups, but the median IC50 of subtype A
gp160s were significantly lower than for subtype C (P = 0.006)
(Fig 3D). When we analyzed the gp160s of the two subtypes
PLOS ONE | www.plosone.org
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Figure 2. Infectivity of TZM-bl cells with Env pseudo-typed
viruses. Viruses were tested from NTM, TM and infected children (IC)
with results expressed in relative luciferase units (RLU). *Probability that
the groups are similar is ,0.05.
doi:10.1371/journal.pone.0069274.g002

We next tested the autologous neutralization by plasma from
mothers collected one week pre-partum (before nevirapine was given
and termed ‘‘screen’’) and between 16 and 18 weeks post-partum
(termed ‘‘late’’) as well as corresponding plasma from both infected
and uninfected children. For these assays we utilized the
corresponding mothers pseudo-typed (Fig. 5A) and JRFL pseudo-typed (Fig. 5B) virus strains. Plasma of week 16 from one IU
infected child (101) and one uninfected child (161) were missing.
TM: Transmitting mothers, NTM: non-transmitting mother, Pos: positive, Neg: negative, sna: sample not available.
doi:10.1371/journal.pone.0069274.t001
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TM/NTM Subtype
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208,000

Time-point
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CD4 count
(wk0) cells/ml
Viral load (wk16)
RNA/copies/ml
Viral load
(screen) RNA
copies/ml

Table 1. Characteristics of transmitting mothers, non-transmitting mothers and children.

Time-point
late plasma
(week)

Subject

Viral load (wk16)
PCR Wk0 RNAcopies/ml

Time-point Time-point
clones
plasma

HIV-1 Neutralization Linked with MTCT

Figure 3. Inhibition of Env pseudo-typed viruses from NTM, TM
and infected children (IC) expressed as IC50’s. (A) sCD4, (B) aCD4
Ab OKT4 and (C) CCR5 antagonist Maraviroc. NTM are represented by
dots, TM by squares, and IC by triangles. Competition with Maraviroc of
subtype A (open diamonds) versus subtype C (open dots) viruses is
shown in D. **Probability that the groups are similar is ,0.01.
doi:10.1371/journal.pone.0069274.g003
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Figure 4. DC-SIGN mediated capture and transfer of Env pseudo-typed viruses from NTM, TM and infected children (IC). (A) Quantity
of Env pseudo-typed virus captured by Raji-DC-SIGN cells as determined by CA-p24. (B) Extent of infection of TZM-bl cells by captured Env pseudotyped viruses expressed in relative luciferase units (RLU). (C and D) Linear regression analysis of the V1–V5 number of PNGS and virus capture by RajiDC-SIGN cells, in (C) NTM and TM and (D) in IC. NTM are represented by circles, TM by squares, and IC by triangles.
doi:10.1371/journal.pone.0069274.g004

corresponding child (Fig. 5C). We found significantly better
neutralization of the gp160s of the IU TM than of the PP/BF TM
by screen plasma (P = 0.002), by late plasma (P = 0.03) and by
children’s plasma (P = 0.02). We also analyzed the neutralization
of the IU and PP/BF infected children’s env clones by screen
plasma and late plasma of the corresponding mothers (Fig. 5C)
and by autologous plasma (Fig. 5D). Screen plasma from the PP/
BF transmitting mothers tended to neutralize the gp160s of
children less than plasma from the IU TM (P = 0.07), but no
difference in neutralization was found with the late plasma’s.
Autologous gp160s of the corresponding child were better
neutralized by screen plasma from PP/BF TM than from NTM
(P = 0.06 and P = 0.02) (data not shown). The IU infected
children’s plasma tended to neutralize autologous gp160s better
than the PP/BF infected children (P = 0.06). At the lowest plasma
dilution tested (1:36) 2/3 PP/BF transmitted viruses could not be
inhibited to 50% while 1/3 was 50% inhibited at a dilution of
1:80, indicating possible immune escape of these viruses. In
conclusion we found that viruses of IU transmission pairs were
better neutralized than those of PP/BF transmissions.

There were no differences observed between TM and NTM in the
concentration of overall IgG in plasma’s (data not shown). There
was also no correlation observed between viral load and the
autologous neutralization by plasma’s (P = 0.78, r2 = 0.004) (data
not shown). We found that plasma from TM was significantly
better in neutralizing autologous gp160 than the NTM (P = 0.002
for screen plasma and P = 0.006 for late plasma) and that plasma
from infected children neutralized better than plasma from
uninfected children (P = 0.02). The JRFL gp160 was also better
neutralized by TM than by NTM (P = 0.07 for screen plasma and
P = 0.02 for late plasma) but the 50% inhibitory dose (ID50) was
0.5 to 0.9log lower than in the autologous neutralization
experiments. In conclusion, autologous plasma from both TM
and infected children neutralized gp160s from the corresponding
mothers more efficiently than plasma from the NTM and the
uninfected infants.

Neutralization of Plasma more Evident in IU
Transmissions than in PP/BF Transmissions
To further investigate differences in neutralization activity
between the different transmission routes, we analyzed separately
the viruses of the mothers who transmitted IU and those who
transmitted PP or BF. We tested neutralization using autologous
screen plasma and late plasma as well as plasma from the
PLOS ONE | www.plosone.org
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Table 2. Neutralization of Env pseudo-typed viruses by panel of Nabs (2G12, b12, 2F5 and 4E10).

Subject

Subtype

Category

Route

2G12 (IC50 mg/ml) B12 (IC50 mg/ml)

2F5 (IC50 mg/ml) 4E10 (IC50 mg/ml)

90P02

A

TM

IU

.30

3.88

14.41

4.33

90P05

A

TM

IU

.30

4.05

13.21

5.30
2.82

91P26

A

IC

IU

.30

2.17

11.57

919342

A

IC

IU

0.52

15.29

5.43

2.48

100P37

A

TM

IU

.30

.30

5.54

0.61

100P21

A

TM

IU

.30

.30

8.16

1.42

100P32

A

TM

IU

.30

.30

0.47

0.09

101P19

A

IC

IU

.30

3.87

1.71

1.00

130P17

C

TM

PP/BF

.30

2.64

.30

1.62

130P16

C

TM

PP/BF

.30

4.83

.30

1.56

130P10

C

IC

PP/BF

.30

0.37

.30

4.94

250P10

A/C

TM

IU

3.26

1.93

2.52

1.41

250P11

A/C

TM

IU

0.89

4.60

1.41

2.05

251P22

A/C

IC

IU

0.04

2.63

2.78

1.06

290P04

A

TM

IU

0.66

0.93

0.39

0.67

290P01

A

TM

IU

2.30

0.50

0.21

0.56

291P187

A

IC

IU

0.08

1.16

0.60

0.32

300P29

A

TM

PP/BF

.30

.30

4.03

3.68

300P31

A

TM

PP/BF

.30

.30

3.50

0.42

301P91

A

IC

PP/BF

2.14

.30

0.20

0.23

370P23

A

TM

PP/BF

.30

.30

3.03

1.65

370P19

A

TM

PP/BF

.30

.30

0.61

0.28

371P131

A

IC

PP/BF

.30

.30

0.58

0.27

160P40

A

NTM

N/A

.30

.30

2.92

2.88

160P38

A

NTM

N/A

.30

.30

1.52

1.44

200P20

A

NTM

N/A

.30

0.11

0.71

0.51

200P22

A

NTM

N/A

.30

0.02

1.84

0.98

270P03

C

NTM

N/A

.30

1.86

.30

3.79

270P07

C

NTM

N/A

.30

1.25

.30

2.03

380P02

A

NTM

N/A

0.56

0.03

0.42

0.24

380P04

A

NTM

N/A

1.36

0.04

0.62

0.87

TM; transmitting mother, NTM: non-transmitting mother, IC: infected child, IU: in utero, PP: peri-partum, BF: breastfeeding, Bold: IC50,30.
doi:10.1371/journal.pone.0069274.t002

No Difference in IgG Binding to Subtype B gp140
Envelope Trimer between Plasma’s from TM and NTM

Multi-variate Analysis of env Sequences
In an earlier report we analyzed the gp120 env sequences for
TM, NTM and infected children and identified two PNGS (N234
and N339) which associated with viruses that preferentially
underwent MTCT [20]. We performed a multi variable analysis
to test correlations of the presence of one or both PNGS with
infectivity, CD4 interaction, CCR5 interaction, DC-SIGN interaction and neutralization sensitivity. We could not identify
significant associations with alterations within these sites and the
phenotypes tested (data not shown).

To rule out that differences in total IgG confused our results, we
measured the concentration of IgG in the plasma’s of mothers and
children. We found no difference between TM and NTM but the
HIV-1 infected children demonstrated higher levels of IgG in their
plasma than the uninfected children (12,6 g/l and 5.7 g/l,
P = 0.02) (data not shown). We also investigated the levels of
IgG that binds to gp140 envelope trimer in an ELISA assay. To
enhance the statistical power of the experiment we included 14
additional plasma samples from NTM from our cohort. We found
no differences between TM and NTM. Similar results were
obtained with a subtype A gp140 trimer. We also investigated the
gp140 binding properties of plasma of the infected children
extended with 21 uninfected children from our cohort and again
no differences were found (data not shown).

PLOS ONE | www.plosone.org

Discussion
We studied the viral and immunologic correlates of the HIV-1
subtype A or C or A/C recombinant gp160 envelope proteins
from seven mother/child pairs whose children were infected either
during gestation or soon after birth and from four NTM with viral
loads and CD4 counts in the same range. We found no viral
correlates that could have facilitated HIV-1 MTCT, but TM
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Figure 5. Plasma neutralization of NTM, TM, infected children (IC) and non-IC. (A) Neutralization of Env pseudo-typed viruses carrying NTM
and TM gp160. (B) Neutralization of Env pseudo-typed viruses carrying the JRFL gp160. Neutralization from NTM is represented by dots, from TM by
squares, from NIC by diamonds and from IC by triangles. (C) Autologous neutralization of Env pseudo-typed viruses carrying TM gp160/gp41, divided
into IU and PP/BF and (D) neutralization of children’s Env pseudo-typed viruses. Neutralization by plasma from IU TM is represented by closed dots,
from PP/BF TM by open dots, from IU IC by closed triangles and from BF IC by open triangles. The dashed line indicates the lowest plasma dilution
tested (1R48). *Probability that the groups are similar is ,0.05, **Probability that the groups are similar is ,0.01.
doi:10.1371/journal.pone.0069274.g005

demonstrated higher plasma neutralization capacity than NTM.
IU TM neutralized their autologous Env pseudo-typed viruses and
those of their infants to significantly higher levels than mothers
that transmitted HIV-1 either PP or via BF. Furthermore, plasma
from infants infected IU were able to neutralize their autologous
Env pseudo-typed viruses as well as those from their mothers to
higher levels in comparison to those infected PP/BF, who showed
no autologous neutralization capacity.
It has been hypothesized that HIV-1 variants with a replication
fitness advantage are those more likely to be transmitted or
dominate and selectively outgrow upon infection. Although
replication capacity cannot be directly extrapolated from infectivity, a study using single-cycle viruses from subtype C infected
MTCT pairs has reported that such viruses from children have a
higher fitness than those generated from the mothers and that this
is restricted to the V1V5 region of the envelope [15]. Earlier
studies found no difference in infectivity between mothers and
children’s gp160s tested in a single-cycle assay on TZM-bl cells
[21,23]. We found here that viruses derived from children were
less infectious for TZM-bl cells than those derived from their
mothers. This may reflect differences in time of sampling. We
studied viruses soon after transmission whereas other studies were
PLOS ONE | www.plosone.org

conducted with viruses amplified later allowing time for viruses to
adapt and gain fitness. Additionally, the discrepancies observed
may be partially explained by differences in the cell lines used for
pseudo-virus production and the envelope/backbone ratio used in
generating the pseudo-typed viruses [50,51].
The vast majority of HIV-1 infections are initiated by a single or
a limited number of viral variants, irrespective of transmission
route or HIV-1 subtype, indicating a severe bottleneck to
transmission [17,52]. X4 viruses are rarely transmitted. The
variants undergoing both horizontal as well as MTCT are mainly
R5 [4,5,53]. Whether this results from selection of R5 viruses, the
early replication outgrowth of R5 over X4 strains or the limited
presence of X4 viruses at the site of exposure is still unknown [54–
56]. A higher affinity for HIV-1 binding to CD4 or the CCR5
coreceptor may provide a level of selection, however, in
concordance with earlier publications studying horizontal as well
as vertical transmission cases we did not find differences between
transmitted and not transmitted variants in ability to interact with
either CD4 or CCR5 [13,14,16].
HIV-1 MTCT requires virus to cross a mucosal barrier, be it
via the placenta or the oral/gastrointestinal tract. Mucosal
infection can be heightened through the interaction of HIV-1
8
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In both PP and BF transmission HIV-1 has to cross the oral or
intestinal mucosal layer. Ex vivo experiments have shown that
HIV-1 infected macrophages and to a lesser extent HIV-1
lymphocytes are able to migrate across the oral and intestinal
epithelium [40]. For IU transmission the virus has to transgress the
trophobastic layer that separates the placenta from the fetal blood
and the amniotic fluid. Experiments were performed with the
BeWo polarized trophoblast cell line that mimics the barrier
between maternal and fetal blood and between placenta and
amniotic fluid [35]. As shown by these experiments PBMCs,
lymphocytes and macrophages are able to fuse to the apical side of
the trophoblasts, resulting in release of infectious virus at the basal
lateral side of the monolayer in parallel with infection through the
mucosa of the fetal digestive tract [35].
During gestation a considerable amount of maternal IgG is
transferred to the fetus and additionally IgG is transferred to the
newborn child by breastfeeding. This process is mediated by the
FcRn receptor expressed on trophoblasts and intestinal mucosa
which binds maternal IgG followed by transcytosis and release at
the basal side of the mucosa into the fetal blood, into the amnion
fluid or the digestive tract of the child [35,63]. This mechanism
may provide a means whereby HIV-1 in IgG/HIV-1 complexes
can bind FcRn and be transported to the fetus or the newborn
child. This process will be favored by higher concentrations of Env
binding IgG. Although others have reported stronger binding
(gp160, V3 and gp41 directed) IgG Abs in TM opposed to NTM
we found higher levels of NAbs favor MTCT [37,38]. The exact
conformation of the HIV-1/IgG complex that is able to bind in
the proper manner to FcRn and thereby be transcytosed may have
restrictions, steric or otherwise. High affinity between IgG and the
virus particle may therefore be significant for both neutralizing
activity as well as for FcRn transcytosis of the virus-IgG complex.
Ab dependent enhancement of HIV-1 binding and infection of
certain cell types has been previously demonstrated in vitro and
may indeed explain for our observed findings [45,64–66].
We demonstrate here that in the cohort we investigated the
neutralizing function of maternal Abs, rather than preventing,
associates with a higher risk of IU MTCT. In future studies it
would therefore be prudent to consider the different routes of
exposure when comparing immunologic factors associated with
MTCT, in both the mother and the infant. These results indicate
that different mechanisms may support viral transmission via the
variant routes of exposure. More so, our results suggest caution
when considering using NAbs for passive immunization to prevent
IU MTCT and in inducing high levels of NAbs in pregnant
vaccine recipients. Larger studies need to be performed to support
these findings and especially to characterize the specificities and
properties of such induced Abs and to understand which responses
can be beneficial opposed to being detrimental.

with an array of C-type lectins, including DC-SIGN, expressed on
DCs lying below the mucosal epithelium [41–43]. DC-SIGN
allows for the capture of virus and its heightened transfer to CD4+
lymphocytes via trans-infection. We found no difference in the
efficiency of DC-SIGN capture and transfer of virus to TZM-bl
cells between NTM, TM and children. A positive correlation,
however, was found between the number of PNGS with DCSIGN capture when analyzing env clones from TM as well as
NTM but not for viruses from children. This suggests that viruses
transferred to children are not selected based on their capacity for
binding DC-SIGN. It should be noted that the pseudo-typed
viruses studied were produced within the human C33A cell line
and therefore likely possess the relevant post-translational glycosylation modifications relevant to the human in vivo situation
[50,57]. Furthermore, other C-type lectins expressed on DCs can
capture HIV-1, however here we specifically focused on DCSIGN since genetic polymorphisms within this molecule have been
associated with risk of transmission [44]. It remains to be assessed
whether other molecules expressed on DCs can associate with
heightened viral capture and transfer and thereby contribute to
MTCT.
HIV-1 subtype B R5 Env variants derived from acutely infected
individuals via horizontal transmission have been shown to possess
NAb inhibitory profiles similar to those derived from chronically
infected individuals [58–61]. However, other studies analyzing
viruses undergoing sexual transmission indicate that these variants
encode gp120s with a compact structure and a reduced number of
PNGS that are more sensitive to the effects of NAbs [17,59].
Sensitivity to NAbs may therefore not be a disadvantage in
horizontal transmission where the recipient is Ab naı̈ve. In MTCT
the situation is different where the child inherits HIV-1 Abs from
the mother. It has recently been shown that NAbs can provide
selection for a gp120/gp41 envelope with the capacity to induce
more potent and broadly neutralizing Abs [62]. Here we found no
differences between the viruses from mothers and children for
inhibition with the broadly NAbs b12, 2G12, 2F5 and 4E10,
suggesting no such selection regarding envelope structure.
Reports studying mother child pairs have shown better
neutralization by NTM than by TM suggesting a protective role
by Abs [24,25]. Here we found no such effect and actually
identified a stronger neutralization profile of autologous viruses
within the TM opposed to NTM group. In accordance, we found
no neutralization of JRFL with plasma from NTM whilst we did
observe neutralization of the same virus with plasma from NTM.
One limitation to our study, and inherent to all such studies, is that
the exact timings of transmission are not known and where viral
adaptations can occur. When we compare the TM to NTM
neutralizations of either autologous virus or JRFL the same effect
is seen for both early and late plasma from mothers and where the
neutralization of viruses from children, all amplified from a time
point between plasma sampling of the mother, show similar
results. These findings collectively indicate that the observed effect
of heightened neutralization is unlikely to be due to differences in
timings of transmissions and the subsequent development of
escape or reduced neutralization sensitivities. Another limitation to
our study is the low number of mother child pairs where HIV-1
transmission occurred and especially when considering subgroupings. However, it is clear that autologous NAb responses,
in either the mother or infant, do not protect against MTCT, and
may in fact be detrimental when considering IU transmissions. We
highlight that additional studies of larger cohorts need to be
undertaken to confirm such conclusions, but our results indicate
that autologous NAb responses are not protective.

PLOS ONE | www.plosone.org

Methods
Study Population and Ethics Statement
The study was approved by an Independent Ethics Committees
(IEC) in the Netherlands, the STEG-METC (ref no R01–089). In
the absence of an operational IEC in Rwanda at the time, the
Ministry of Health’s Treatment and Research AIDS Center
(TRAC), the Rwandan National Malaria program (PNLP) and the
‘‘Cellule de recherché’’ at the CHK acknowledged the approval of
the Dutch IEC. All women provided written informed consent for
both themselves and their children. Plasma samples were utilized
from HIV-1 positive mothers (n = 30) and their infants from
Rwanda [20]. All women received single dose Nevirapine at onset
of labor. Maternal plasma was collected prior to delivery (screen),
9
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pseudo-typed virus and tested for infectivity as described below
and the infectious clones were selected.

at labor (early) and week 16 and 18 (late) after delivery. Child’s
plasma was collected at delivery (early) and 16 weeks (late) of age.
All children were breastfed during the 16 week study period.

Cells and Transfections
HIV-1 RNA Extraction and Amplification

C33A cells and TZM-bl cells (obtained through the NIH
ARRRP from Dr. John C. Kappes, Dr. Xiaoyun Wu and
Tranzyme Inc., Durham, NC) were maintained in Dulbecco’s
modified Eagle’s medium (DMEM; Invitrogen, Breda, The
Netherlands), each supplemented with MEM nonessential amino
acids and 10% foetal calf serum (FCS), penicillin (100 U/ml) and
streptomycin (100 mg/ml) as previously described (58). One day
prior to transfection 2.56106 C33A cells were seeded in a 25 cm2
culture flask. After 24 h the cells were transfected using the CaPi
method. In short: HEPES-buffer (50 mM HEPES pH7.1,
250 mM NaCl, 1.5 mM Na2HPO4) was added to 9 mg of the
envelope containing plasmids and 3.9 mg of plasmid pSG3Denv in
a volume of 293 ml, mixed well and 40 ml of 2M CaCl2 was added
and again mixed well. After 45 min incubation at rt the mixture
was added to the C33A cells. As a positive control JRFL envelope
was used and pSG3Denv alone for the negative control. After 18 h
the medium was refreshed and the pseudo-typed virus containing
supernatant was harvested after 48 h of incubation. Virus was
stored at 280uC. The virus concentration was quantified by
measuring its CA-p24 antigen content by ELISA.

HIV-1 RNA was isolated from plasma samples according to the
method of Boom et al [67]. Viral RNA was converted to cDNA as
previously described [6] with an input of 6,000 copies RNA per
amplification. We selected this copy number to limit recombination events that can arise during PCR amplification and to
minimize the risk associated with such an approach. Reverse
transcription of RNA to single-stranded cDNA was performed
using the SuperScript III protocol according to the manufacturer’s
instructions (Invitrogen Life Technologies, Carlsbad, CA) with a
modification. RNA, Betaine (1 M) deoxynucleoside triphosphates
(0.5 mM each), and 0.25 mM primer OFM19 (59-GCACTCAAGGCAAGCTTTATTGAGGCTTA-39; nucleotides [nt]
9604 to 9632 of the HXB2 sequence) were incubated for 5 min
at 65uC to denature secondary structure of the RNA. First-strand
cDNA synthesis was carried out in 20 ml reaction mixtures with
First-Strand Buffer containing 5 mM dithiothreitol, 2 U/ml of an
RNase inhibitor (RNaseOUT), and 10 U/ml Super- Script III.
The reaction mixture was incubated at 55uC for 65 min and
inactivated by being heated to 65uC for 15 min. The resulting
cDNA was used immediately for PCR.

Sequencing and Phylogenetic Analysis
Gene Amplification

The infectivity competent env clones were sequenced using the
ABI PRISM Big Dye Terminator Kit (Applied Biosystems, Forster
City, CA, USA). Sequences were assembled using the CodonCode
Aligner program (CodonCode Corporation, Dedham, USA).
Alignments were performed taking the translation codons into
account and the sequences were translated into amino acids using
the BioEdit program (Tom Hall, Ibis Therapeutics, Carlsbad, CA,
USA). Phylogenetic analysis of the envelopes was performed with
the Neighbor-Joining (N-J) method of MEGA version 4 (Tamura,
Dudley, Nei, and Kumar 2007). Positions containing an alignment
gap were included for pair wise sequence analysis. The number
PNGS was determined using the program available at the HIV
Sequence Database (http://www.hiv.lanl.gov/content/sequence/
GLYCOSITE/glycosite.html). The gp160 envelope sequences
have been submitted to GenBank under accession numbers
JX508855 - JX508885.

Full-length rev/env genes (including parts of the first exon of the
tat gene; the entire vpu, rev, and env genes; and parts of the nef gene)
were amplified by nested PCR from plasma-derived viral cDNA as
previously described with minor changes [6]. Briefly, 20 ml of bulk
cDNA (containing 100 to 1,000 viral templates) was subjected to
first-round PCR in a volume of 50 ml. PCR was performed by
using an Expand High Fidelity PCR system (Roche Diagnostic
Corporation, Indianapolis, IN) in 5ml Expand PCR buffer
containing 1.5 mM MgCl2, 0.2 mM of each deoxynucleoside
triphosphate, and 0.2 mM of Vif1 (59-GGGTTTATTACAGGGACAGCAGAG-39; nt 4900 to 4923) and OFM19 primers. The
following cycling conditions were used: 93uC for 2 min followed
by 10 cycles of 93uC for 10 s, 58uC for 30 s, and 68uC for 5 min,
and followed by 20 cycles of 93uC for 10 s, 58uC for 30 s, and
68uC for 5 min extended with 20 s with each cycle, with a final
extension of 68uC for 7 min. Second-round PCR was performed
by using 5 ml of the first-round PCR product and primers EnvA
(59 GGCTTAGGCATCTCCTATGGCAGGAAGAA-39; nt
5954 to 5982) and EnvN (59-CTGCCAATCAGGGAAGTAGCCTTGTGT-39; nt 9145 to 9171) under the same
conditions used for the first-round PCR.

Single-cycle Infections and Inhibition Assays
One day prior to infection, 176103 TZM-bl cells were added to
a 96-well plate and cultured overnight. Infections were performed
in 200 ml with 1 pg CA-p24 virus input and medium supplemented with 10mg/ml DEAE dextran. Two days post-infection the
medium was removed, the cells were washed once with PBS and
lyzed in reporter lysis buffer (Promega, Madison, WI). Luciferase
activity was measured using the Luciferase Assay kit (Promega)
and a Glomax luminometer according to the manufacturer’s
instructions (Turner BioSystems, Sunnyvale, CA). All infections
were performed in duplicate and repeated at least once. Cells
infected with negative control pseudo-typed virus were used to
correct for background luciferase activity. The infectivity of each
mutant without inhibitor was defined as 100%. Non-linear
regression curves were determined and IC50 or ID50 values were
calculated using Inhibitor versus Response variant of the Non
Linear Regression function of GraphPad Prism version 5.00 for
Windows, (GraphPad Software, San Diego California USA, www.
graphpad.com) and a significance level of P,0.05 was used for all
the analyses.

Construction of Envelope Clones
The final PCR products of the predicted size (63.2 kb) were
ligated into the pcDNA3.1.V5-His TOPO TA vector according to
the manufacturer’s instructions (Invitrogen Life Technologies,
Carlsbad, CA) and transformed into Stbl4 cells by electroporation
(Invitrogen Life Technologies, Carlsbad, CA). Reaction mixtures
were plated on LB-Amp (ampicillin; 100mg/ml) plates and
cultured 24 h at 30uC. Colonies were screened with a colony
PCR using primers T7 (59-TAA TAC GAC TCA CTA TAG GG
A-39) and FGS021 (59-CTT TCA TTG CCA CTG TCT TCT
GCT-39). Clones containing the right size and orientation were
grown in LB-Amp (ampicillin; 100 mg/ml) and plasmid was
isolated with the Bioké NucleoSpin Kit (Machery-Nagel, Düren,
Germany). The plasmids were screened by generating Env
PLOS ONE | www.plosone.org
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The program Factor Correction was used to remove multiplicative between-session variation [68]. For determination of the
infectivity of the pseudo-typed viruses three step serial dilutions of
virus were used. In inhibition experiments an amount of virus
equal to 1pg of p24/well was used. In experiments with Maraviroc
or OKT-4 (eBioscience, San Diego, CA) TZM-bl cells were
incubated with 3 step dilutions of inhibitor for 30 min at 37u
before the pseudo-typed virus was added. For inhibition with
sCD4-183 pseudo-typed virus was incubated with 3 step dilutions
for 30 min at 37u before infection of the cells. The maximum
concentration of sCD4, Maraviroc and OKT4 was 10 mg/ml,
10 ng/ml and 30 ng/ml respectively.

skimmed milk in TBS. Serial dilutions of plasma in TBS/2%
milk/20% sheep serum were added and incubated for 2 h
followed by 5 washes with TBS/0.05% Tween-20. Goat- antihuman Fc-HRP (Jackson Immuno Research, England) 1:1000
diluted in TBS/2% milk/20% sheep serum was added and
incubated for 30 min. followed by 5 washes with TBS/Tween. All
reactions were performed in 100 ml/well. Colorimetric detection
was performed by adding 50 ml of 1%TMB (Sigma-Aldrich, the
Netherlands), 0.01% H2O2, 1 M Sodium Acetate, 0.1 M citric
acid and the reaction was stopped by adding 50 ml 0.8 M H2SO4/
well when appropriate and absorption at 450 nm was measured.

Statistical Analysis

Virus Capture and Transfer by Raji-DC SIGN cells

To avoid confounding of the analysis caused by the use of more
than one data point derived from each of the members in the
groups of NTM, TM and infected children we performed the
Kruskall-Wallis test to determine within and between individual
differences in our results on infectivity, CD4 interaction, CCR5
interaction, DC-SIGN interaction and neutralization sensitivity
and with a Bonferroni correction for multiple testing. No
significant differences were found between the individuals within
each group and therefore the Mann-Whitney test was used to
analyze the differences between the groups. Analysis of the
association of the presence of one or both PNGS N234 and N339
with infectivity, CD4 interaction, CCR5 interaction, DC-SIGN
interaction and neutralization sensitivity was done with the
multivariate logistic regression analysis using PASW 17.0.
hypotheses testing, all variables were introduced through forward
stepwise procedure. A significance level of P,0.05 was used for all
the analyses.

For the DC-SIGN capture and transfer experiments 50 ml of
Raji or Raji-DC-SIGN cells (206106 cells/ml) were mixed with
150 ml of pseudo-typed virus equal to 50 ng/ml CA-p24 and
incubated for 2 h at 37u, washed 46 with ice cold PBS and
resuspended in 90 ml of culture medium. 10 ml of this suspension
was used in the CA-p24 ELISA to quantify the amount of virus
captured by DC-SIGN, corrected for non-specific binding to the
Raji cells. 15 ml of the suspension was used to infect TZM-bl cells.
After 48 h the TZM-bl cells were lyzed and luciferase activity was
measured as described above.

HIV-1 Neutralization
Assays measuring HIV-1 inhibition using NAbs b12, 2F5, 4E10
and 2G12, maternal or children’s plasma were performed as
previously described [69], using virus input equal to 1 pg CA-p24
of pseudo-typed virus/well. Before infection the virus was
incubated with 3 step dilutions of NAb or plasma for 30 min at
37u. The maximum Ab concentration used in neutralization assays
was 10 mg/ml. The lowest dilution of plasma was 1:36. All plasma
samples were heat inactivated at 56uC for 30 min before use.
Plasma from a seronegative donor was used as a negative control
and showed no neutralization activity at 1:36 dilution.
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